PubMed Health⌕ Search

Biomedical subjects

B Neidhardt

Publications and source records attributed to B Neidhardt.

At least 37 records · Page 2Linked to original sources
PubMed1983

[Heart surgery in a female patient with blood group Oh (Bombay phenotype)].

A 62-year-old woman with stenosing coronary artery disease had the rare blood group Oh (Bombay phenotype). After prophylactic deep-freeze conservation of autologous blood, direct myocardial revascularization was successfully accomplished under extracorporeal circulation. Three deep-freeze units of erythrocyte concentrates were used. Both operation and postoperative wound healing progressed without complication.

ABO Blood-Group System↗
PubMed1982

[Disorders of hemostasis in liver cirrhosis. 2. Therapy].

Hemostatic changes in liver cirrhosis regularly have complex causes. In addition to a quantitative deficiency of hemostatic factors, also qualitative changes in coagulation factors, disturbances in coagulation factor metabolism and possible iatrogenic disturbances in plasmatic and thrombocytic hemostatic mechanism are to be considered. To diagnose a deficit of hemostatic factors is no problem, but to answer the question which of the numerous pathogenetic factors dominates in an individual case at this moment is very difficult and often impossible.

Antithrombin III↗
PubMed1981

[Autologous blood transfusion with deep frozen stored blood in cardiac surgery (author's transl)].

Cardiac operations were made possible by deep freezing of autologous blood in 187 out of 262 cardiac patients (71%) using only the patients' own blood. In only 75 patients (29%) was additional homologous blood transfusion necessary. It should be possible to lower further the requirements for donor blood by using an even stricter indication for the transfusion of homologous blood and by further improvements in techniques and organization. Autologous blood donation and transfusion of deep frozen conserved own blood were both tolerated very well by patients with cardiac disease. The advantages of deep frozen conservation of autologous blood in cardiac surgery are so convincing that they fully compensate for disadvantages of high cost and work required.

Adolescent↗
PubMed1981

[Gastrectomy in congenital factor VII deficiency with substitution of factor VII concentrate].

Case report of a 57-year old man, who had a severe congenital factor VII deficiency (factor VII 2%), and who was substituted with factor VII concentrate, before undergoing a subtotal gastrectomy. The patient was previously asymptomatic. The operation and wound-healing was without complication. That the patient, despite his factor VII deficiency, showed no clinical signs of a bleeding diathesis, raises the question, whether in such a case a factor VII substitution is necessary. 3 children of the patient (2 sons aged 25 and 23 years, and an 18 year old daughter) were examined and found to be heterozygote carriers to a degree of 32%, 42% and 60% factor VII; none showed sure signs of a bleeding tendency related to factor VII deficiency.

Adolescent↗
PubMed1979

[A prospective multi-centre study of the response of metastatic gastrointestinal tumours (author's transl)].

In a prospective, multi-centre, randomized study of 109 patients with metastatic gastro-intestinal adenocarcinomas the response rate, survival time and side-effects of two drug combinations, carmustin +5-fluorouracil and carmustin + ftorafur, were compared (same carmustin dosage in both groups). Response to the treatment was 32.7% in those receiving carmustin +5-fluorouracil, 26.3% in those on carmustin + ftorafur. This difference occurred among the 42 patients with gastric adenocarcinoma (33.3% compared with 25%), as well as in 11 with pancreatic adenocarcinoma, and in 56 with colorectal adenocarcinoma (32.1% and 28.6%). Median survival time for 5-fluorouracil + carmustin was 330 days, double that for ftorafur + carmustin (163 days). Bone-marrow toxicity (leukopenia, thrombopenia) was below 10% for both drug combinations. Alopecia occurred in only a few patients. Gastro-intestinal toxicity was common (20% and 18.5%, respectively), but there was no difference between the two groups. The somewhat lower effectiveness of ftorafur compared with 5-fluorouracil was probably due to the deliberately smaller dosage of the former.

Adenocarcinoma↗
PubMed1978

[Treatment results of therapy resistant acute leukemias with 7 cystostatic agents (TRAMPCO-scheme)].

Treatment of therapy-resistant acute leukemia with 7 cytostatics (TRAMPCO) 13 adult patients with acute leukemia, primarily and secondarily resistant to other combined therapy, as well as 2 untreated patients were treated with 7 cytostatic drugs according to the so called TRAMPCO-regimen. 5 complete remissions and 5 partial remissions were obtained corresponding to a degree of response of 66%. The duration of remission was relatively short with 1 to 5 months, in one case more than 6 months. The toxicity of the combined therapy could be tolerated, the personal subjective tolerance was good. The Trampco-regiment therefore represents a realistic possibility in the treatment of acute leukemia resistant to other forms of treatment.

Acute Disease↗
PubMed1978

[What are the dangers of splenectomy in Hodgkin's disease?].

Splenectomy is a surgical procedure of medium severity, the mean lethality rate is 1%, the complication rate 10 to 20%. The surgical risk is dependent upon age and general condition of the patient, the severity of the disease, and the experience of the surgeon. The risk of late complications due to surgery is determined mainly by infections as well as ileus, requiring relaparatomy. The risk of infections is higher in children than in adults: one has to be aware of miningitis and sepsis in about 10% of the patients; half of those cases end lethal. An analysis of advantages versus risks of splenectomy must be made for each patient individually. For optimal treatment it is necessary to know the stage of the disease. Concerning M. Hodgkin, explorative laparatomy combined with splenectomy should be performed in stage I to III A. If, however, the surgical risk is rather high primarily and if there are no therapeutical consequences to be expected, splenectomy should not be performed because of the known risks and disadvantages.

Adult↗
PubMed1978

[Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)].

153 patients with inoperable malignant tumors were treated by the so-called synchronization therapy with vincristine and ifosfamide. 13 complete remissions (8.5%) and 47 partial remissions (30.7%) were obtained. 5 times cessation of tumor growth occurred (3.3%). In 88 cases the therapy failed (57.5%), but in 11 cases a subjective improvement was noted. The most favourable results of treatment were obtained in cases of malignant lymphoma, small cell carcinoma of the lung and testicular carcinomas. Although the duration of remission was short in most cases, it could be demonstrated, that a targeted polychemotherapy is possible using the proliferation kinetic data in addition to the knowledge of the cell-phase-specific effect of cytostatic drugs. This therapy can succeed in causing a tumor regression even in metastatic carcinomas.

Adult↗